ImmunityBio is exploding higher today as investor optimism builds around the company's lead immunotherapy candidate, Anktiva. The stock is benefiting from positive sentiment regarding an upcoming FDA decision on a bladder-cancer label expansion expected by January 6, 2027, alongside reports of successful trial results and strategic oncology network expansion by the company's chairman. Additionally, the stock is drawing fresh retail attention as market participants draw comparisons to recent momentum in the broader biotechnology sector.